NYMC Faculty Publications
First Page
26
Last Page
26
Document Type
Article
Publication Date
7-26-2016
Department
Medicine
Abstract
Background
The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.
Case presentation
We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.
Conclusion This highly refractory pre-B Ph− ALL was induced to complete remission after one course of single agent blinatumomab.
Recommended Citation
Li, Z., & Liu, D. (2016). Cell therapy must be regulated as medicine. Experimental Hematology & Oncology, 5, 26. doi:10.1186/s40164-016-0055-0
Publisher's Statement
Originally published in Experimental Hematology & Oncology. Licensed under CC-BY 4.0. https://doi.org/10.1186/s40164-016-0055-0
